×
0.407368421052632 0.407368421052632 0.315789473684211 0.309473684210526 0.342105263157895 0.365789473684211 0.35 0.348947368421053
Stockreport

CytomX teams up with Amgen to develop EGFR-targeting antibodies for cancer [Seeking Alpha]

CYTOMX THERAPEUTICS (CTMX)  More Company Research Source: Seeking Alpha
Last cytomx therapeutics earnings: 11/7 04:57 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.cytomx.com
PDF CytomX teams up with Amgen to develop EGFR-targeting antibodies for cancerCytomX Therapeutics (NASDAQ:CTMX) inks astrategic collaboration with Amgen (NASDAQ:AMGN) to co-develop a CytomX Probody T-cell engaging bispecific against the well-validated cancer target Epidermal Growth Factor Receptor (EGFR).Probody T-cell engaging bispecifics are antibody constructs that the company says are capable of directing cytotoxic T cells in tumor microenvironments. In preclinical studies, CytomX's Probody versions of EGFRxCD3 bispecific therapeutics induced tumor regressions and increased the therapeutic window for the target.Under the terms of the partnership, the companies will co-develop a Probody T-cell engaging bispecific against EGFRxCD3. CytomX will lead early development with Amgen taking over later development and commercialization. Global late-stage development costs will be shared. Amgen will pay $40M upfront and purchase $20M of CTMX common stock. CytomX will be eligible for up to $455M [Read more]

IMPACT SNAPSHOT EVENT TIME: CTMX
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS